🎗️ OncologyOne single-dose 225 mg strength gemcitabine intrave
Inlexzo
gemcitabine intravesical
INLEXZO treats adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.
Form
One single-dose 225 mg strength gemcitabine intrave
Uses
1
Side effects
4
Category
Oncology
01
What is Inlexzo used for?
- INLEXZO is indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BC
02
gemcitabine intravesical side effects
Common side effects of gemcitabine intravesical include:
Urinary frequency
Urinary tract infection
Dysuria
Micturition urgency
CommonModerateLess common
03
gemcitabine intravesical warnings & precautions
- Risks in Patients with Perforated Bladder : Evaluate the bladder before the intravesical insertion of INLEXZO.
- Do not administer to patients with a perforated bladder or in whom the integrity of the bladder mucosa has been compromised.
- ( 4 , 5.1 ) Risk of Metastatic Bladder Cancer with Delayed Cystectomy : Delaying cystectomy can lead to the development of metastatic bladder cancer,
Loading FDA data…
04
Frequently asked questions
05
Related medications
Share
Share this drug info.
Help friends and family understand Inlexzo in plain language.
Disclaimer: This information is sourced from the FDA openFDA database and is provided for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before starting or changing medication.